The costs and time needed to commercialize a new drug are escalating – exceeding 8 years and over $2 billion. A big factor in these staggering rates is the increasing complexity of clinical trials, driven in large part by study designs needing more endpoints to demonstrate product value, including data from medical health devices. Against this backdrop, the clinical trials industry needs disruption more than ever before.
This is where Artificial Intelligence (AI) and emerging technologies come in. By cutting costs, improving data quality, and reducing trial durations, AI, machine learning and deep learning techniques are driving clinical trial efficiencies, optimizing end-to-end clinical trial processes, and helping pharma companies bring new drugs and therapies to the market faster.
How did VISTAAR Help?
VISTAARs clinical Trials Intelligence’AI-driven protocol designs powered by AI algorithms and deep learning techniques can make clinical trials more intelligent in numerous ways. VISTAAR clinical artificial intelligence can provide pharmaceutical researchers the updated data that can help to determine whether patients will drop out of studies and whether trials will be successful or not. Using predictive algorithms and AI techniques, trial risks can be mitigated well before they become big problems, thereby keeping trials on track and on budget.
